Impact of circulating tumor cell (CTC) nucleus size on outcomes with abiraterone acetate (AA) therapy in men with metastatic castration-resistant prostate cancer (mCRPC)

被引：2
|
作者：
Gill, David Michael
Agarwal, Neeraj
Hahn, Andrew W.
Johnson, Eric
Poole, Austin
Carroll, Emma
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 06期
关键词：
D O I：
10.1200/JCO.2017.35.6_suppl.253
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
253
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Impact of prior response to abiraterone acetate (AA) on subsequent activity of docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).
    Azad, Arun
    Lester, Renee
    Heng, Daniel Yick Chin
    Eigl, Bernhard J.
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [32] Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer
    Zhang, Tian
    Zhu, Jason
    George, Daniel J.
    Armstrong, Andrew J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (04) : 473 - 485
  • [33] Baseline analysis of circulating tumor cell (CTC) enumeration and androgen receptor (AR) localization in men with metastatic castration-resistant prostate cancer (mCRPC) in TAXYNERGY.
    Tagawa, Scott T.
    Galletti, Giuseppe
    Antonarakis, Emmanuel S.
    Tasaki, Shinsuke
    Gjyrezi, Ada
    Worroll, Daniel
    Portella, Luigi
    Kirby, Brian J.
    Stewart, John
    Zaher, Atef
    Saad, Fred
    Vanhuyse, Marie
    Suri, Shalu
    Lannin, Timothy B.
    Gruber, Conor
    Pratt, Erica
    Sonpavde, Guru
    Eisenberger, Mario A.
    Nanus, David M.
    Giannakakou, Paraskevi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [34] Evaluating the safety of abiraterone acetate (AA) and docetaxel (D) administered in combination in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Tagawa, Scott T.
    Nanus, David M.
    Posadas, Edwin M.
    Petrylak, Daniel Peter
    Bruce, Justine Yang
    Lim, Emerson A.
    Peng, Weimin
    Maul, Raymond Scott
    Gonzalez, Martha
    Tran, Namphuong
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [35] Body composition and clinical outcomes in men with metastatic castration-resistant prostate cancer (mCRPC)
    Hahn, A. W.
    Tidwell, R. S.
    Surasi, D. S.
    Msaouel, P.
    Efstathiou, E.
    Zurita-Saavedra, A. J.
    Tu, S-M.
    McQuade, J. L.
    Fogelman, D.
    Starbuck, M. W.
    Subudhi, S. K.
    Corn, P.
    Pilie, P. G.
    Aparicio, A.
    Logothetis, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S538 - S538
  • [36] Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer
    Mckay, R. R.
    Werner, L.
    Fiorillo, M.
    Nakabayashi, M.
    Kantoff, P. W.
    Taplin, M-E
    PROSTATE CANCER AND PROSTATIC DISEASES, 2016, 19 (04) : 398 - 405
  • [37] Use of Prednisone With Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
    Auchus, Richard J.
    Yu, Margaret K.
    Nguyen, Suzanne
    Mundle, Suneel D.
    ONCOLOGIST, 2014, 19 (12): : 1231 - 1240
  • [38] Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer
    R R McKay
    L Werner
    M Fiorillo
    M Nakabayashi
    P W Kantoff
    M-E Taplin
    Prostate Cancer and Prostatic Diseases, 2016, 19 : 398 - 405
  • [39] Germline variant in SLCO2B1 and response to abiraterone acetate plus prednisone (AA) in men with metastatic castration-resistant prostate cancer (mCRPC).
    Hahn, Andrew W.
    Patel, Darshan
    Gill, David Michael
    Froerer, Camryn
    Nussensveig, Roberto
    Poole, Austin
    Hale, Peter
    Farnham, James M.
    Maughan, Benjamin Louis
    Cannon-Albright, Lisa A.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [40] Chromosomal instability (CIN) biomarker in circulating tumor cells (CTC) may predict for therapy resistance in metastatic castration-resistant prostate cancer (mCRPC)
    Keegan, N. M.
    Schonhoft, J.
    Barnett, E.
    Cohn, E. D.
    Zhao, J. L.
    Carbone, E. A.
    Zanone, M. R.
    Anderson, A.
    Wenstrup, R.
    Scher, H. I.
    ANNALS OF ONCOLOGY, 2021, 32 : S653 - S653
12345